Applied Dna Sciences INC

BNB Plus Corp. has entered into a Settlement Agreement to terminate its Digital Services and Strategic Advisor Agreements with Cypress LLC and Cypress Management LLC, involving a $1 million payment and issuance of preferred stock.

BNB Plus Corp. announced its common stock will be delisted from Nasdaq effective July 14, 2026, due to non-compliance with the minimum bid price requirement, and will transition to trading on the OTCQB Venture Market.

BNB Plus Corp. has amended its Registration Rights Agreement, extending the filing date for registration statements related to its registrable securities.

BNB Plus Corp. has closed additional warrant inducement agreements, bringing total anticipated gross proceeds from its recent financing initiatives to $4.3 million.

BNB Plus Corp. announced initial commitments of $4.1 million in convertible preferred stock financing, with a target of $5 million, to support a strategic review of its digital asset and biotechnology businesses.

BNB Plus Corp. received a delisting notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement and is ineligible for a compliance period due to prior reverse stock splits.

BNB Plus Corp. reports a significant net loss in Q1 2026, driven by its strategic pivot to a digital asset treasury strategy and associated fair value losses on digital assets.

Applied DNA Sciences reports continued net losses and a going concern warning as it strategically exits non-core businesses to focus on nucleic-acid production for biopharmaceuticals.

Applied DNA Sciences is shifting its focus to Therapeutic DNA Production Services after exiting its DNA Tagging and Security Products and Services business, reporting a net loss of $6.0 million for the six months ended March 31, 2025.

Applied DNA Sciences saw revenue growth in Q1 2025 but continues to experience net losses as it focuses on Therapeutic DNA Production Services and exits its DNA Tagging and Security Products and Services business.

Applied DNA Sciences reported its Q3 2024 financial results, highlighting a net loss and raising concerns about its ability to continue as a going concern.

Applied DNA Sciences reported a net loss for the second quarter of 2024 and faces substantial doubt about its ability to continue as a going concern.

BNB Plus Corp. (formerly Applied DNA Sciences, Inc.) has completed a strategic pivot to a digital asset treasury model focused on BNB, while reporting a significantly wider net loss for fiscal year 2025.

Applied DNA Sciences is prioritizing its Therapeutic DNA Production Services and exploring the potential divestiture of its DNA Tagging and Security Products and Services business segment.

Applied DNA Sciences has filed an amendment to its annual report to include information that was intended to be incorporated by reference from its proxy statement.

BNB PLUS CORP. Director Joseph D. Ceccoli was granted 77,038 incentive stock options with an exercise price of $0.69, vesting over time.

BNB Plus Corp. Director and 10% owner James Haft was granted 77,038 non-qualified stock options with an exercise price of $0.69, vesting over one year.

BNB PLUS CORP. Director James Haft acquired 93,000 stock options with a $1.31 exercise price, vesting over four installments through February 2027.

BNB PLUS CORP. CEO Clay Shorrock was granted 84,388 stock options, comprising incentive and non-qualified options, with an exercise price of $2.52 per share.

BNB PLUS Corp.'s Chief Financial Officer, Beth Jantzen, was granted 84,388 stock options with an exercise price of $2.52, vesting quarterly.

Applied DNA Sciences CEO Clay Shorrock acquired 18,691 shares of common stock through a restricted stock unit grant, vesting in 90 days.

BNB Plus Corp. calls a Special Meeting to seek stockholder approval for a reverse stock split, aiming to regain Nasdaq compliance and facilitate strategic alternatives amidst delisting concerns.

BNB Plus Corp., formerly Applied DNA Sciences, Inc., announced its name change effective November 13, 2025, signaling a strategic shift towards a BNB-based digital asset treasury strategy.

Applied DNA Sciences calls a Special Meeting to approve warrant exercises, increase authorized shares, and expand its equity incentive plan to support its new BNB digital asset strategy.

Applied DNA Sciences is holding its 2025 Annual Meeting of Stockholders virtually on May 22, 2025, to vote on key proposals including a reverse stock split, warrant exercises, and an amendment to the equity incentive plan.

Applied DNA Sciences reminds shareholders to vote on the Warrant Exercise Proposal before the reconvened Special Meeting on February 14, 2025, following an adjournment due to lack of quorum.

Applied DNA Sciences is holding a special stockholder meeting on January 23, 2025, to vote on the exercisability of certain common stock purchase warrants issued in connection with a prior securities offering.

BNB Plus Corp. files an S-1/A to register 18.7 million shares for resale by selling stockholders, detailing its new BNB-focused digital asset treasury strategy and ongoing LineaRx biopharmaceutical business.

Applied DNA Sciences is shifting its primary focus to a BNB-focused digital asset treasury strategy, backed by a private placement raising up to $57.6 million, despite ongoing financial losses and going concern doubts.

Applied DNA Sciences has filed an amendment to its Form S-1 registration statement, pertaining to the resale of up to 41,640,625 shares of common stock issuable upon the exercise of outstanding warrants.

Applied DNA Sciences is registering for resale up to 41.6 million shares of common stock issuable upon the exercise of outstanding warrants held by selling stockholders.

Applied DNA Sciences is seeking to raise capital through an offering of units, each consisting of common stock or pre-funded warrants, Series A and B warrants, and placement agent warrants.

Applied DNA Sciences aims to raise approximately $8.97 million through a unit offering to further develop its Therapeutic DNA Production and MDx Testing Services.

Comstock MultiChain Fund has restructured its holdings in BNB Plus Corp through a warrant inducement agreement and initiated a strategic review of the company's business units.

KGPLA Holdings LLC and Michael Komaransky have jointly filed a Schedule 13D, disclosing beneficial ownership of 1,798,500 shares of BNB Plus Corp. common stock, representing 19.9% of the outstanding shares, acquired through a private placement of Series B-1 Convertible Preferred Stock.

Comstock MultiChain Fund and affiliates disclose a 9.9% beneficial ownership stake in BNB PLUS CORP., signaling potential strategic discussions.

L1 Capital Global Opportunities Master Fund, Ltd. has increased its beneficial ownership in BNB PLUS CORP. to 8.7%, acquiring 539,892 shares through warrant exercises.

Off the Chain LP and Off the Chain Capital, LLC have disclosed a 9.99% beneficial ownership stake in BNB Plus Corp., primarily through common stock and warrants.

Sabby Management, LLC and affiliated entities reported a 4.9% beneficial ownership stake in BNB Plus Corp. common stock as of December 31, 2025.

Anson Funds Management LP and its affiliates have filed an Amendment No. 3 to Schedule 13G, reporting a 4.9% beneficial ownership in Applied DNA Sciences, Inc. as of September 30, 2025.

S.H.N. Financial Investments Ltd. has amended its beneficial ownership in Applied DNA Sciences Inc., now holding 3.4% of the common stock through warrants.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Applied DNA Sciences, Inc. through a Schedule 13G filing.